Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02002767 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT02002767 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 19 participants.
The verdict
NCT02002767, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the single-dose pharmacokinetics (PK) of velpatasvir (formerly GS-5816) in participants with severe renal impairment using matched healthy participants as a control group.
Interventions
- DRUG Velpatasvir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2013-12-16 |
| Est. Completion | 2014-06-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02002767
The ClinicalTrials.gov registry entry for NCT02002767 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Velpatasvir is the first listed.
NCT02002767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02002767 about?
NCT02002767 is a clinical study titled "Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment". The primary objective of the study is to evaluate the single-dose pharmacokinetics (PK) of velpatasvir (formerly GS-5816) in participants with severe renal impairment using matched healthy participants as a control group.
What is the current status of trial NCT02002767?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2013-12-16. Estimated completion is 2014-06-09.
What interventions are being tested in trial NCT02002767?
The interventions under investigation include: Velpatasvir (DRUG).
Who is sponsoring clinical trial NCT02002767?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.